Trust Co. of Virginia VA increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the second quarter, Holdings Channel reports. The institutional investor owned 97,251 shares of the company’s stock after buying an additional 3,906 shares during the period. Johnson & Johnson makes up about 2.1% of Trust Co. of Virginia VA’s investment portfolio, making the stock its 9th largest position. Trust Co. of Virginia VA’s holdings in Johnson & Johnson were worth $11,797,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. Grassi Investment Management raised its stake in Johnson & Johnson by 60.3% in the first quarter. Grassi Investment Management now owns 75,571 shares of the company’s stock valued at $8,177,000 after buying an additional 28,414 shares in the last quarter. Peachtree Investment Advisors Inc. raised its position in Johnson & Johnson by 2.6% in the first quarter. Peachtree Investment Advisors Inc. now owns 22,178 shares of the company’s stock worth $2,400,000 after buying an additional 562 shares during the period. CENTRAL TRUST Co acquired a new position in Johnson & Johnson during the first quarter worth $22,676,000. Central Bank & Trust Co. raised its position in Johnson & Johnson by 0.4% in the first quarter. Central Bank & Trust Co. now owns 19,479 shares of the company’s stock worth $2,108,000 after buying an additional 74 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Johnson & Johnson by 14.6% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 629,505 shares of the company’s stock worth $68,112,000 after buying an additional 80,067 shares during the period. 65.32% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) traded up 0.73% on Friday, reaching $118.13. The company’s stock had a trading volume of 7,941,065 shares. The firm has a market capitalization of $323.19 billion, a price-to-earnings ratio of 22.01 and a beta of 0.61. Johnson & Johnson has a 52 week low of $92.58 and a 52 week high of $126.07. The company has a 50 day moving average of $119.23 and a 200 day moving average of $116.66.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. On average, analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 2.71%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s dividend payout ratio is currently 60.15%.
JNJ has been the subject of a number of recent analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Friday, June 3rd. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $109.97 price objective for the company. in a research note on Monday, June 6th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, June 6th. Goldman Sachs Group Inc. set a $121.00 price objective on Johnson & Johnson and gave the stock a “neutral” rating in a research note on Monday, June 13th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $109.00 price objective (up previously from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $120.19.
In other news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.